Tags

Type your tag names separated by a space and hit enter

Intestinal absorption of 59Fe from neutron-activated commercial oral iron(III)-citrate and iron(III)-hydroxide-polymaltose complexes in man.
Arzneimittelforschung. 1987 Jan; 37(1A):105-7.A

Abstract

Commercial oral iron preparations (drops) containing trivalent iron either as a citrate (C) or hydroxide-polymaltose complex (HP) were labelled with 59Fe in the thermal neutron flux of a research reactor. No measurable differences were observed between the original commercial preparation and the neutron-activated samples. In an intraindividual comparison oral doses of 100 mg 59Fe were administered as an aqueous 59Fe(II)-ascorbate solution (= reference), C (-59Fe) and HP (-59Fe) to starved subjects with normal and depleted iron stores. Two weeks later the whole body retention of absorbed 59Fe was measured and used for the calculation of 59Fe-absorption. Subjects with normal Fe-stores absorbed means a +/- SEM +/- SD = 8.53 +/- 0.29 +/- 1.2% of the 59Fe from the aqueous 59Fe(II)-ascorbate solution, 1.58 +/- 0.12 +/- 0.49 of the C-59Fe and 0.81 +/- 0.06 +/- 0.27% of the HP-59Fe. Subjects with depleted Fe-stores absorbed means a +/- SD = 17 +/- 3% of the 59Fe from the aqueous 59Fe(II)-ascorbate solution and only 2.4 +/- 1% from the HP-59Fe. The relative bioavailabilities were reduced from 100% (reference = Fe(II)-ascorbate) to 19% for the C-Fe and to 9.5% for the HP-Fe in subjects with normal Fe-stores. In subjects with depleted iron stores the relative bioavailability was decreased from 100 to 14% for the HP-Fe. Oral iron preparations with a relative bioavailability less than 10% or less than 30% are considered to be therapeutically ineffective or insufficient, respectively.

Authors

No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

3566863

Citation

Heinrich, H C.. "Intestinal Absorption of 59Fe From Neutron-activated Commercial Oral iron(III)-citrate and iron(III)-hydroxide-polymaltose Complexes in Man." Arzneimittel-Forschung, vol. 37, no. 1A, 1987, pp. 105-7.
Heinrich HC. Intestinal absorption of 59Fe from neutron-activated commercial oral iron(III)-citrate and iron(III)-hydroxide-polymaltose complexes in man. Arzneimittelforschung. 1987;37(1A):105-7.
Heinrich, H. C. (1987). Intestinal absorption of 59Fe from neutron-activated commercial oral iron(III)-citrate and iron(III)-hydroxide-polymaltose complexes in man. Arzneimittel-Forschung, 37(1A), 105-7.
Heinrich HC. Intestinal Absorption of 59Fe From Neutron-activated Commercial Oral iron(III)-citrate and iron(III)-hydroxide-polymaltose Complexes in Man. Arzneimittelforschung. 1987;37(1A):105-7. PubMed PMID: 3566863.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intestinal absorption of 59Fe from neutron-activated commercial oral iron(III)-citrate and iron(III)-hydroxide-polymaltose complexes in man. A1 - Heinrich,H C, PY - 1987/1/1/pubmed PY - 1987/1/1/medline PY - 1987/1/1/entrez SP - 105 EP - 7 JF - Arzneimittel-Forschung JO - Arzneimittelforschung VL - 37 IS - 1A N2 - Commercial oral iron preparations (drops) containing trivalent iron either as a citrate (C) or hydroxide-polymaltose complex (HP) were labelled with 59Fe in the thermal neutron flux of a research reactor. No measurable differences were observed between the original commercial preparation and the neutron-activated samples. In an intraindividual comparison oral doses of 100 mg 59Fe were administered as an aqueous 59Fe(II)-ascorbate solution (= reference), C (-59Fe) and HP (-59Fe) to starved subjects with normal and depleted iron stores. Two weeks later the whole body retention of absorbed 59Fe was measured and used for the calculation of 59Fe-absorption. Subjects with normal Fe-stores absorbed means a +/- SEM +/- SD = 8.53 +/- 0.29 +/- 1.2% of the 59Fe from the aqueous 59Fe(II)-ascorbate solution, 1.58 +/- 0.12 +/- 0.49 of the C-59Fe and 0.81 +/- 0.06 +/- 0.27% of the HP-59Fe. Subjects with depleted Fe-stores absorbed means a +/- SD = 17 +/- 3% of the 59Fe from the aqueous 59Fe(II)-ascorbate solution and only 2.4 +/- 1% from the HP-59Fe. The relative bioavailabilities were reduced from 100% (reference = Fe(II)-ascorbate) to 19% for the C-Fe and to 9.5% for the HP-Fe in subjects with normal Fe-stores. In subjects with depleted iron stores the relative bioavailability was decreased from 100 to 14% for the HP-Fe. Oral iron preparations with a relative bioavailability less than 10% or less than 30% are considered to be therapeutically ineffective or insufficient, respectively. SN - 0004-4172 UR - https://www.unboundmedicine.com/medline/citation/3566863/Intestinal_absorption_of_59Fe_from_neutron_activated_commercial_oral_iron_III__citrate_and_iron_III__hydroxide_polymaltose_complexes_in_man_ L2 - https://antibodies.cancer.gov/detail/CPTC-DLC1-1 DB - PRIME DP - Unbound Medicine ER -